Trade Novartis Adr Repsg 1 - USD - NVS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.20 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.025457% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003235% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Novartis AG ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 96.96 |
Open* | 98.43 |
1-Year Change* | 9.79% |
Day's Range* | 98.3 - 98.81 |
52 wk Range | 74.09-105.56 |
Average Volume (10 days) | 2.51M |
Average Volume (3 months) | 46.42M |
Market Cap | 224.83B |
P/E Ratio | 30.45 |
Shares Outstanding | 2.10B |
Revenue | 52.14B |
EPS | 3.25 |
Dividend (Yield %) | 3.53726 |
Beta | 0.54 |
Next Earnings Date | Jul 18, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 98.77 | 0.70 | 0.71% | 98.07 | 98.89 | 97.57 |
Jun 1, 2023 | 96.96 | 0.03 | 0.03% | 96.93 | 97.13 | 96.20 |
May 31, 2023 | 96.13 | 0.00 | 0.00% | 96.13 | 96.46 | 95.15 |
May 30, 2023 | 96.29 | -0.49 | -0.51% | 96.78 | 96.84 | 96.00 |
May 26, 2023 | 97.77 | -0.34 | -0.35% | 98.11 | 98.78 | 97.52 |
May 25, 2023 | 97.68 | -0.77 | -0.78% | 98.45 | 98.54 | 97.21 |
May 24, 2023 | 99.77 | -0.36 | -0.36% | 100.13 | 100.19 | 99.06 |
May 23, 2023 | 100.16 | -1.26 | -1.24% | 101.42 | 101.42 | 99.96 |
May 22, 2023 | 100.69 | -0.76 | -0.75% | 101.45 | 101.96 | 100.45 |
May 19, 2023 | 100.78 | 0.79 | 0.79% | 99.99 | 100.96 | 99.97 |
May 18, 2023 | 100.12 | -0.09 | -0.09% | 100.21 | 101.01 | 99.44 |
May 17, 2023 | 100.97 | -1.19 | -1.16% | 102.16 | 102.23 | 100.62 |
May 16, 2023 | 102.54 | -0.56 | -0.54% | 103.10 | 103.18 | 102.50 |
May 15, 2023 | 102.83 | -0.40 | -0.39% | 103.23 | 103.45 | 102.53 |
May 12, 2023 | 103.07 | 0.02 | 0.02% | 103.05 | 103.75 | 102.62 |
May 11, 2023 | 103.31 | 0.17 | 0.16% | 103.14 | 103.53 | 102.65 |
May 10, 2023 | 103.57 | 0.00 | 0.00% | 103.57 | 103.83 | 102.62 |
May 9, 2023 | 104.63 | 0.18 | 0.17% | 104.45 | 104.89 | 104.05 |
May 8, 2023 | 104.64 | 0.07 | 0.07% | 104.57 | 105.31 | 104.00 |
May 5, 2023 | 104.67 | 0.96 | 0.93% | 103.71 | 104.85 | 103.35 |
Novartis Adr Repsg 1 - USD Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 51742 | 52877 | 49898 | 48624 | 46017 |
Revenue | 51742 | 52877 | 49898 | 48624 | 46017 |
Cost of Revenue, Total | 14998 | 15435 | 14400 | 13930 | 13555 |
Gross Profit | 36744 | 37442 | 35498 | 34694 | 32462 |
Total Operating Expense | 42545 | 41188 | 39746 | 39538 | 31824 |
Selling/General/Admin. Expenses, Total | 14190 | 14815 | 14093 | 14319 | 13690 |
Research & Development | 9088 | 9041 | 8484 | 8386 | 8154 |
Depreciation / Amortization | 158 | 109 | 64 | 50 | 179 |
Unusual Expense (Income) | 3402 | 1173 | 2503 | 2284 | -4309 |
Other Operating Expenses, Total | 449 | 653 | 538 | 607 | 549 |
Operating Income | 9197 | 11689 | 10152 | 9086 | 14193 |
Interest Income (Expense), Net Non-Operating | -543 | 14628 | -146 | -36 | -5 |
Other, Net | -283 | -180 | -128 | -110 | -93 |
Net Income Before Taxes | 8371 | 26137 | 9878 | 8940 | 14095 |
Net Income After Taxes | 6955 | 24018 | 8071 | 7147 | 12800 |
Minority Interest | 0 | 3 | 1 | -5 | -3 |
Net Income Before Extra. Items | 6955 | 24021 | 8072 | 7142 | 12797 |
Net Income | 6955 | 24021 | 8072 | 11732 | 12611 |
Income Available to Common Excl. Extra. Items | 6955 | 24021 | 8072 | 7142 | 12797 |
Income Available to Common Incl. Extra. Items | 6955 | 24021 | 8072 | 11732 | 12611 |
Dilution Adjustment | |||||
Diluted Net Income | 6955 | 24021 | 8072 | 11732 | 12611 |
Diluted Weighted Average Shares | 2197 | 2260 | 2296 | 2319 | 2344 |
Diluted EPS Excluding Extraordinary Items | 3.16568 | 10.6288 | 3.51568 | 3.07978 | 5.45947 |
Dividends per Share - Common Stock Primary Issue | 3.32525 | 3.19907 | 3.08737 | 2.83413 | 2.93645 |
Diluted Normalized EPS | 4.47075 | 11.1183 | 4.40641 | 3.86715 | 3.79006 |
Total Extraordinary Items | 4590 | -186 | |||
Interest Expense (Income) - Net Operating | 260 | -38 | -336 | -38 | 6 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total revenue | 13208 | 13001 | 12842 | 13085 | 12814 |
Revenue | 13208 | 13001 | 12842 | 13085 | 12814 |
Cost of Revenue, Total | 3829 | 3837 | 3657 | 3749 | 3755 |
Gross Profit | 9379 | 9164 | 9185 | 9336 | 9059 |
Total Operating Expense | 10352 | 11052 | 10674 | 10857 | 9962 |
Selling/General/Admin. Expenses, Total | 3401 | 3699 | 3404 | 3589 | 3498 |
Research & Development | 2272 | 2318 | 2263 | 2251 | 2256 |
Depreciation / Amortization | 153 | 42 | 42 | 39 | 35 |
Interest Expense (Income) - Net Operating | 46 | -28 | 90 | 96 | 102 |
Unusual Expense (Income) | 298 | 1145 | 1068 | 996 | 295 |
Other Operating Expenses, Total | 353 | 39 | 150 | 137 | 21 |
Operating Income | 2856 | 1949 | 2168 | 2228 | 2852 |
Interest Income (Expense), Net Non-Operating | -212 | -222 | -219 | -202 | -203 |
Other, Net | 96 | 14 | -30 | 16 | 20 |
Net Income Before Taxes | 2740 | 1741 | 1919 | 2042 | 2669 |
Net Income After Taxes | 2294 | 1466 | 1575 | 1695 | 2219 |
Minority Interest | -1 | 0 | -2 | -1 | 3 |
Net Income Before Extra. Items | 2293 | 1466 | 1573 | 1694 | 2222 |
Net Income | 2293 | 1466 | 1573 | 1694 | 2222 |
Income Available to Common Excl. Extra. Items | 2293 | 1466 | 1573 | 1694 | 2222 |
Income Available to Common Incl. Extra. Items | 2293 | 1466 | 1573 | 1694 | 2222 |
Diluted Net Income | 2293 | 1466 | 1573 | 1694 | 2222 |
Diluted Weighted Average Shares | 2120 | 2158 | 2180 | 2211 | 2237 |
Diluted EPS Excluding Extraordinary Items | 1.0816 | 0.67933 | 0.72156 | 0.76617 | 0.99329 |
Dividends per Share - Common Stock Primary Issue | 0 | 3.32525 | 0 | 0 | 0 |
Diluted Normalized EPS | 1.20956 | 1.14055 | 1.12553 | 1.14122 | 1.10442 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 36910 | 45718 | 29673 | 29504 | 35563 |
Cash and Short Term Investments | 18726 | 28113 | 11293 | 11234 | 15718 |
Cash | 2877 | 3396 | 3750 | 3247 | 3121 |
Cash & Equivalents | 4640 | 9011 | 5908 | 7865 | 10150 |
Short Term Investments | 11209 | 15706 | 1635 | 122 | 2447 |
Total Receivables, Net | 9894 | 9621 | 10036 | 10337 | 11036 |
Accounts Receivable - Trade, Net | 8066 | 8005 | 8217 | 8301 | 8739 |
Total Inventory | 7175 | 6666 | 7131 | 5982 | 6956 |
Prepaid Expenses | 911 | 1102 | 943 | 898 | 812 |
Other Current Assets, Total | 204 | 216 | 270 | 1053 | 1041 |
Total Assets | 117453 | 131795 | 127778 | 118370 | 145563 |
Property/Plant/Equipment, Total - Net | 12195 | 13106 | 13939 | 13746 | 15696 |
Property/Plant/Equipment, Total - Gross | 26304 | 28708 | 29894 | 28676 | 34028 |
Accumulated Depreciation, Total | -14109 | -15602 | -15955 | -14930 | -18332 |
Goodwill, Net | 29301 | 29595 | 29999 | 26524 | 35294 |
Intangibles, Net | 31644 | 34182 | 36809 | 28787 | 38719 |
Long Term Investments | 1606 | 2268 | 11611 | 10538 | 9789 |
Note Receivable - Long Term | 948 | 973 | 922 | 624 | 908 |
Other Long Term Assets, Total | 4849 | 5953 | 4825 | 8647 | 9594 |
Total Current Liabilities | 28656 | 30208 | 33059 | 28264 | 29607 |
Accounts Payable | 5146 | 5553 | 5403 | 5424 | 5556 |
Accrued Expenses | 5334 | 5100 | 5336 | 5058 | 5105 |
Notes Payable/Short Term Debt | 3635 | 3606 | 7319 | 4844 | 6430 |
Current Port. of LT Debt/Capital Leases | 2492 | 2896 | 2558 | 2248 | 3190 |
Other Current Liabilities, Total | 12049 | 13053 | 12443 | 10690 | 9326 |
Total Liabilities | 58111 | 64140 | 71180 | 62896 | 66949 |
Total Long Term Debt | 21782 | 24523 | 27978 | 22056 | 22470 |
Long Term Debt | 20244 | 22902 | 26259 | 20353 | 22470 |
Deferred Income Tax | 2686 | 3070 | 3141 | 5867 | 7475 |
Minority Interest | 81 | 167 | 68 | 77 | 78 |
Other Liabilities, Total | 4906 | 6172 | 6934 | 6632 | 7319 |
Total Equity | 59342 | 67655 | 56598 | 55474 | 78614 |
Common Stock | 890 | 901 | 913 | 936 | 944 |
Retained Earnings (Accumulated Deficit) | 63540 | 70989 | 57157 | 59274 | 82191 |
Treasury Stock - Common | -92 | -48 | -53 | -80 | -69 |
Unrealized Gain (Loss) | -198 | 206 | |||
Other Equity, Total | -4798 | -4187 | -1419 | -4656 | -4658 |
Total Liabilities & Shareholders’ Equity | 117453 | 131795 | 127778 | 118370 | 145563 |
Total Common Shares Outstanding | 2119.61 | 2234.94 | 2256.82 | 2265.01 | 2311.17 |
Capital Lease Obligations | 1538 | 1621 | 1719 | 1703 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 32114 | 36910 | 36954 | 38142 | 37236 |
Cash and Short Term Investments | 12260 | 18930 | 19103 | 19758 | 18814 |
Cash & Equivalents | 12000 | 7517 | 8726 | 3625 | 13852 |
Short Term Investments | 260 | 11413 | 10377 | 16133 | 4962 |
Total Receivables, Net | 9183 | 8334 | 8680 | 8910 | 8678 |
Accounts Receivable - Trade, Net | 8916 | 8066 | 8422 | 8643 | 8409 |
Total Inventory | 7886 | 7175 | 6779 | 6880 | 6997 |
Other Current Assets, Total | 2785 | 2471 | 2392 | 2594 | 2747 |
Total Assets | 112241 | 117453 | 118464 | 122910 | 125218 |
Property/Plant/Equipment, Total - Net | 12348 | 12195 | 11731 | 12206 | 12861 |
Goodwill, Net | 29481 | 29301 | 28668 | 29113 | 29636 |
Intangibles, Net | 30451 | 31644 | 31888 | 33367 | 34853 |
Long Term Investments | 2555 | 2554 | 2491 | 2580 | 2906 |
Other Long Term Assets, Total | 5292 | 4849 | 6732 | 7502 | 7726 |
Total Current Liabilities | 30549 | 28656 | 28160 | 27646 | 29807 |
Accounts Payable | 5426 | 5146 | 4693 | 4969 | 5083 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 7166 | 6127 | 7204 | 7247 | 6902 |
Other Current Liabilities, Total | 17957 | 17383 | 16263 | 15430 | 17822 |
Total Liabilities | 60182 | 58111 | 57644 | 59985 | 63678 |
Total Long Term Debt | 21985 | 21782 | 21235 | 23784 | 24373 |
Long Term Debt | 20396 | 20244 | 19732 | 22232 | 22796 |
Capital Lease Obligations | 1589 | 1538 | 1503 | 1552 | 1577 |
Deferred Income Tax | 2727 | 2686 | 2719 | 3122 | 3384 |
Minority Interest | 83 | 81 | 78 | 81 | 164 |
Other Liabilities, Total | 4838 | 4906 | 5452 | 5352 | 5950 |
Total Equity | 52059 | 59342 | 60820 | 62925 | 61540 |
Common Stock | 842 | 890 | 890 | 890 | 901 |
Retained Earnings (Accumulated Deficit) | 51253 | 58544 | 60000 | 62095 | 60699 |
Treasury Stock - Common | -36 | -92 | -70 | -60 | -60 |
Total Liabilities & Shareholders’ Equity | 112241 | 117453 | 118464 | 122910 | 125218 |
Total Common Shares Outstanding | 2097.4 | 2119.61 | 2150.98 | 2182.79 | 2212.58 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 6955 | 24018 | 8071 | 7147 | 12800 |
Cash From Operating Activities | 14236 | 15071 | 13650 | 13625 | 14272 |
Cash From Operating Activities | 1873 | 1807 | 2088 | 1852 | 1783 |
Amortization | 5308 | 4306 | 4376 | 3974 | 3428 |
Non-Cash Items | 4404 | -11714 | 3842 | 3369 | -2315 |
Cash Taxes Paid | 1975 | 2342 | 1833 | 1876 | 1506 |
Cash Interest Paid | 696 | 664 | 703 | 793 | 816 |
Changes in Working Capital | -4304 | -3346 | -4727 | -2717 | -1424 |
Cash From Investing Activities | 1468 | 4208 | -13182 | -2226 | -5591 |
Capital Expenditures | -2671 | -2971 | -2585 | -2257 | -2648 |
Other Investing Cash Flow Items, Total | 4139 | 7179 | -10597 | 31 | -2943 |
Cash From Financing Activities | -20562 | -16264 | -2208 | -13627 | -4244 |
Financing Cash Flow Items | 55 | 94 | -199 | 3307 | -119 |
Total Cash Dividends Paid | -7506 | -7368 | -6987 | -6645 | -6966 |
Issuance (Retirement) of Stock, Net | -10552 | -3004 | -2094 | -5332 | -1336 |
Issuance (Retirement) of Debt, Net | -2559 | -5986 | 7072 | -4957 | 4177 |
Foreign Exchange Effects | -32 | -266 | 286 | 69 | -26 |
Net Change in Cash | -4890 | 2749 | -1454 | -2159 | 4411 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 2294 | 6955 | 5489 | 3914 | 2219 |
Cash From Operating Activities | 2957 | 14236 | 10125 | 5404 | 1649 |
Cash From Operating Activities | 377 | 7181 | 5233 | 3207 | 1405 |
Amortization | 1619 | ||||
Non-Cash Items | 1085 | 4404 | 3417 | 2164 | 918 |
Cash Taxes Paid | 348 | 1975 | 1559 | 1239 | 633 |
Cash Interest Paid | 123 | 696 | 475 | 308 | 110 |
Changes in Working Capital | -2418 | -4304 | -4014 | -3881 | -2893 |
Cash From Investing Activities | 10621 | 1468 | 2935 | -2263 | 9365 |
Capital Expenditures | -470 | -2671 | -2024 | -1442 | -859 |
Other Investing Cash Flow Items, Total | 11091 | 4139 | 4959 | -821 | 10224 |
Cash From Financing Activities | -9202 | -20562 | -16568 | -11830 | -9528 |
Financing Cash Flow Items | -169 | 55 | 99 | 97 | 22 |
Total Cash Dividends Paid | -7255 | -7506 | -7506 | -7506 | -7506 |
Issuance (Retirement) of Stock, Net | -2727 | -10552 | -7874 | -5156 | -2448 |
Issuance (Retirement) of Debt, Net | 949 | -2559 | -1287 | 735 | 404 |
Foreign Exchange Effects | 107 | -32 | -173 | -93 | -41 |
Net Change in Cash | 4483 | -4890 | -3681 | -8782 | 1445 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Dodge & Cox | Investment Advisor/Hedge Fund | 0.9685 | 20312680 | -438692 | 2023-03-31 | LOW |
PRIMECAP Management Company | Investment Advisor | 0.7832 | 16427035 | -767845 | 2023-03-31 | LOW |
Franklin Mutual Advisers, LLC | Investment Advisor/Hedge Fund | 0.3288 | 6896403 | 281341 | 2023-03-31 | MED |
Loomis, Sayles & Company, L.P. | Investment Advisor/Hedge Fund | 0.315 | 6607149 | -4338849 | 2023-03-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.2943 | 6173671 | 180186 | 2023-03-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 0.2315 | 4854485 | 78 | 2023-03-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.2128 | 4462383 | -106331 | 2023-03-31 | LOW |
BofA Global Research (US) | Research Firm | 0.1946 | 4081695 | 2425777 | 2023-03-31 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.1736 | 3640036 | 114140 | 2023-03-31 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 0.1722 | 3610783 | -322510 | 2023-03-31 | LOW |
Managed Account Advisors LLC | Investment Advisor | 0.168 | 3522986 | -1190474 | 2023-03-31 | LOW |
Schafer Cullen Capital Management, Inc. | Investment Advisor/Hedge Fund | 0.165 | 3460003 | 672290 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.1453 | 3047444 | -373526 | 2023-03-31 | HIGH |
Goldman Sachs & Company, Inc. | Research Firm | 0.139 | 2916193 | 2739477 | 2023-03-31 | MED |
Principal Global Investors (Equity) | Investment Advisor | 0.1302 | 2730347 | 264310 | 2023-03-31 | LOW |
Parametric Portfolio Associates LLC | Investment Advisor | 0.1273 | 2669848 | 21867 | 2023-03-31 | LOW |
Northern Trust Global Investments | Investment Advisor | 0.1137 | 2383712 | 4188 | 2023-03-31 | LOW |
UBS Financial Services, Inc. | Investment Advisor | 0.0898 | 1883281 | -199411 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.0896 | 1878471 | -9886 | 2023-03-31 | LOW |
Wells Fargo Advisors | Research Firm | 0.0878 | 1841280 | 18484 | 2023-03-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Novartis ADR Company profile
Novartis (NVS) provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. The company has been honoured and received numerous awards for progress in research and development, their working environment, and their corporate responsibility activities. Novartis shares are listed and traded on the SIX Swiss Exchange (symbol “NOVN”) as well as on the New York Stock Exchange in the form of ADR (symbol “NVS”). Get all the latest on Novartis Repsg (NVS) share price at Capital.com.Industry: | Pharmaceuticals (NEC) |
Lichtstrasse 35
BASEL
BASEL-STADT 4056
CH
Income Statement
- Annual
- Quarterly
News

USD/TRY forecast: Turkish lira under pressure from high inflation and low rates
We look at some of the latest USD/TRY predictions as the Turkish lira hits record lows.
17:07, 1 June 2023
Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?
Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?
07:46, 31 May 2023
Google stock forecast 2023-2025
What is the outlook for the tech giant, following a tumultuous 2022?
18:02, 30 May 2023
USD forecast: DXY slides in risk-off market sentiment
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
16:10, 24 May 2023
Oil price forecast: Will WTI and Brent regain momentum in 2023?
Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.
11:38, 22 May 2023
Weekly Roundup: Tech stocks lead the way
US stocks push higher as risk appetite surges despite the uncertainty
13:39, 19 May 2023
USD/JPY continues to build higher towards 138
USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher
11:50, 17 May 2023People also watch
Still looking for a broker you can trust?
Join the 535.000+ traders worldwide that chose to trade with Capital.com